Increased Risk of Cutaneous Immune-Related Adverse Events in Patients Treated with Talimogene Laherparepvec and Immune Checkpoint Inhibitors: A Multi-institutional Cohort Study

Published: 14 February 2023| Version 1 | DOI: 10.17632/2sy8nfx9vp.1
Contributor:
Yevgeniy Semenov

Description

Supplemental file

Files

Categories

Immunotherapy, Melanoma

Licence